In recent years, the demand for novel antifungal therapies has increased several-folds due
to its potential to treat severe biofilm-associated infections. Biofilms are made by the sessile …

Due to their eukaryotic heritage, the differences between a fungal pathogen's molecular
makeup and its human host are small. Therefore, the discovery and subsequent …

Open-access drug discovery provides a substantial resource for diseases primarily affecting
the poor and disadvantaged. The open-access Pathogen Box collection is comprised of …

Fungal organisms are ubiquitous in nature, and progress of modern medicine is creating an
expanding number of severely compromised patients susceptible to a variety of …

Toxoplasma gondii is a cosmopolitan protozoan parasite which affects approximately 30%
of the population worldwide. The drugs currently used against toxoplasmosis are few in …

The current Covid-19 pandemic has underlined the need for a more coordinated and
forward-looking investment in the search for new medicines targeting emerging health care …

Background. Candida auris has spread rapidly around the world as a causative agent of
invasive candidiasis in health care facilities and there is an urgent need to find new options …

Abstract The Pathogen Box is a 400‐strong collection of drug‐like compounds, selected for
their potential against several of the world's most important neglected tropical diseases …

We introduce a free platform for chemoinformatic-based diversity analysis and visualization
of chemical space of user supplied data sets. Platform for Unified Molecular Analysis …

Fungal infections pose a significant and increasing threat to human health, but the current
arsenal of antifungal drugs is inadequate. We screened the Medicines for Malaria Venture …